



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/845,623	04/30/2001	Sudhir Agrawal	47508.528	2601

32254 7590 12/15/2005

KEOWN & ASSOCIATES  
500 WEST CUMMINGS PARK  
SUITE 1200  
WOBBURN, MA 01801

EXAMINER

MCINTOSH III, TRAVISS C

ART UNIT PAPER NUMBER

1623

DATE MAILED: 12/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/845,623

Applicant(s)

AGRAWAL ET AL.

Examiner

Traviss C. McIntosh

Art Unit

1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 15 August 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 18-24 and 27 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 18-24 and 27 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

The Amendment filed August 15, 2005 has been received, entered into the record, and carefully considered. The following information provided in the amendment affects the instant application by:

Claim 18 has been amended.

Claims 1-17 and 25-26 are been canceled.

Remarks drawn to rejections of Office Action mailed February 23, 2005 include:

112 2<sup>nd</sup> paragraph rejections: which have been overcome by applicant's amendments and have been withdrawn.

112 1<sup>st</sup> paragraph rejections: which have been maintained for reasons of record.

An action on the merits of claims 18-24 and 27 is contained herein below. The text of those sections of Title 35, US Code which are not included in this action can be found in a prior Office action.

#### ***Claim Rejections - 35 USC § 112***

The rejection of claims 18-24 and 27 under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of inducing an immune response comprising administering a compound comprising a CpG dinucleotide and an immunomodulatory moiety wherein the immunomodulatory moiety is: 2'-deoxyuridine which is 2 nucleosides in either the 3' or 5' direction of the CpG dinucleotide, or an abasic nucleoside which is 4 or 5 nucleosides in

Art Unit: 1623

the 5' position of the CpG dinucleotide, does not reasonably provide enablement for a method of inducing an immune response comprising administering a compound comprising a CpG dinucleotide and an immunomodulatory selected from the group consisting of one or more abasic nucleoside, 1,3-propanediol linker which may be substituted or unsubstituted, 3'-3' linkage and a modified base-containing nucleoside, wherein the modified base-containing nucleoside is selected from the group consisting of inosine, 2-amino-purine, nebularine, 7-deaza-guanosine, nitropyrrole, nitroindole, deoxyuridine, 4-thio-deoxyuridine, d-isoguanosine, d-iso-5-methylcytosine and P-base is maintained for reasons of record. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Undue experimentation is a conclusion reached by weighing the noted factual considerations set forth below as seen in *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). A conclusion of lack of enablement means that, based on the evidence regarding a fair evaluation of an appropriate combination of the factors below, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.

These factors include:

- (A) The breadth of the claims;
- (B) The nature of the invention;
- (C) The state of the prior art;
- (D) The level of one of ordinary skill;
- (E) The level of predictability in the art;
- (F) The amount of direction provided by the inventor;
- (G) The existence of working examples; and
- (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

**The breadth of the claims - The nature of the invention**

Claim 18 is drawn to a method for inducing an immune response in a mammal comprising: administering to the mammal a compound comprising a CpG dinucleotide and an immunomodulatory moiety wherein the immunomodulatory moiety is selected from the group consisting of: one or more abasic nucleosides, a 1,3-propanediol linker which may be substituted or unsubstituted, a 3'-3' linkage, and a modified base containing nucleoside, wherein the modified base containing nucleoside is selected from the group consisting of: inosine, 2-amino-purine, nebularine, 7-deaza-guanosine, nitropyrrole, nitroindole, deoxyuridine, 4-thio-deoxyuridine, d-isoguanosine, d-iso-5-methylcytosine, and P-base; and wherein the compound has a greater immunostimulatory effect than it would if it lacked the immunomodulatory moiety. Claim 19 limits the animal to a human, claim 20 limits the route of administration. Claims 21 and 22 provide an amount of active agent to be taken. Claim 23 provides that the compound is taken in combination with a vaccine, and claim 24 additionally adds an adjuvant. Claim 27 limits G of the CpG dinucleotides to guanosine, 7-deazaguanosine, or inosine.

**The state of the prior art**

CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) are known to induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Pat. Nos. 6,008,200 and 5,856,462. Phosphorothioate CpG containing oligonucleotides are known to be immunostimulatory (Hutcherson et al. US Patent 5,663,153). Liang et al. teach that phosphorothioate CpG containing oligonucleotides are known to activate human B cells (J. Clin. Invest. 98:1119-1129, 1996). Moldoveanu et al. teach phosphorothioate CpG containing

Art Unit: 1623

oligonucleotides enhance immune response against influenza virus (Vaccine, 16:1216-124, 1998). Moreover, the various modified nucleosides and linkages are known in the art. Yu et al. (Exhibit 3 of declaration filed April 19, 2004) shows that the position of immunomodulatory moieties in relation to the CpG dinucleotide are critical to immunostimulatory function (see abstract). Additionally, Agrawal et al. (US Patent 5,968,909) shows that modification of C or G in the CpG dinucleotide suppresses the immunostimulatory effects of the CpG dinucleotide.

#### **The level of predictability in the art**

The examiner acknowledges the probability and predictability that CpG containing oligonucleotides have immunomodulatory activity. The examiner also acknowledges that phosphorothioate oligonucleotides provide immune stimulation. The art teaches that the location of the immunomodulatory agent is critical for immunostimulatory activity (see Yu et al.). The art is silent with regard to the predictability that any of the cited immunomodulatory moieties are effective in combination with a CpG dinucleotide at inducing an immune response when they are in any location. Moreover, physiological activity of compounds *in vitro* is not indicative of the same activity *in vivo*.

#### **The amount of direction provided by the inventor**

The instant specification is not seen to provide adequate guidance which would allow the skilled artisan to extrapolate from the disclosure and examples provided to use the claimed method commensurate in the scope with the instant claims. There is a lack of data and examples which adequately represent the scope of claim as written. The examiner notes, there has not been provided sufficient instruction or sufficient methodological procedures to support the alleged efficacy of prevention instantly asserted.

Art Unit: 1623

### **The existence of working examples**

The working examples set forth in the instant specification are drawn to the following examples:

Example 1: an in vitro test using mouse spleen lymphocytes cultured with oligonucleotides to determine cell proliferation levels.

Example 2: an in vivo test comprising intraperitoneally administering oligonucleotides to mice and determining spleen weights.

The results shown in figure 2 show that oligonucleotide 131-12 was the only oligonucleotide which is seen to have an increased immunostimulatory effect as compared to the control and oligonucleotide 131-1. Sample 131-1, which comprised a CpG dinucleotide sequence and no immunomodulatory moiety, and 131-13 which comprised a modified C of the CpG dinucleotide sequence showed results similar to that of the control, PBS. The results shown in figure 3 are correlative to those for figure 2, and the only oligonucleotide with increased immunostimulatory effect when compared to the control is sample 133-12, which comprises abasic nucleosides 3 and 4 nucleosides on the 5' side of the CpG dinucleotide.

Moreover, in applicants declaration filed 4/19/2004, they attempted to present evidence showing that additional immunomodulatory moieties have immunostimulatory effects when coupled with a CpG dinucleotide. However, in review of the evidence provided, the examiner has concluded that applicants have failed to show enablement for the broad genus as claimed. For example, applicants showed in figure 1 of exhibit 2 that all three oligonucleotides (105-5, 113-1, and 105-8) showed correlative immunostimulatory effects when compared each other. Thus, the 2'-deoxynitropyrrole moieties (in 105-5 and 105-8) did not add anything to the

Art Unit: 1623

immunostimulatory effects of the CpG containing sample of 113-1. All three oligonucleotides exhibited correlative results, and yet, only two of the oligonucleotides had the 2'-deoxynitropyrrole moiety included therein. Additionally, Figure 2B shows that three phosphorothioate oligonucleotides (113-1, 121-2, and 121-4) have correlative immunostimulatory effects *in vivo*, while figure 2A shows that both 121-2 and 121-4 (phosphorothioate oligonucleotides with 2'-deoxyuridine moieties 2 positions down from the CpG function in either the 3' or 5' direction) have an increased immunostimulatory effect *in vitro* when compared to 113-1 (phosphorothioate oligonucleotide without the 2'-deoxyuridine moiety).

There has not been provided sufficient evidence which would warrant the skilled artisan to accept the data and information provided in the working examples as correlative proof that a compound comprising a CpG dinucleotide and any of the claimed immunomodulatory moieties indeed has efficacy as instantly asserted.

**The quantity of experimentation needed to make and use the invention based on the content of the disclosure**

Indeed, in view of the information set forth *supra*, the instant disclosure is not seen to be sufficient to enable a method of inducing an immune response in a mammal comprising administering a compound comprising a CpG dinucleotide and any of the claimed immunomodulatory moieties as instantly asserted. One skilled in the art could not use the entire scope of the claimed invention without undue experimentation.

Enablement for a single compound cannot provide enablement for the breadth of claims sought in arts which are unpredictable. That is, a single embodiment may provide broad



Art Unit: 1623

enablement in cases involving predictable factors, but more is required in cases involving unpredictable factors, such as chemical or physiological activity. See *Ex parte Hitzeman*, 9 USPQ2d 1821 (BPAI 1987) and *In re Shokal*, 242 F.2d 771, 113 USPQ 283, 285 (CCPA 1957). Due to the fact that Yu teach the criticality of the location, and applicants own declarations show that there is no way to predict what the activity of the compound might have, the examiner believes that the factors are considered to be unpredictable.

Applicant's arguments filed August 15, 2005 have been fully considered but they are not persuasive. Applicants argue, and include a declaration stating that following the teachings of the specification with only routine experimentation, similar results are obtained with additional modifications. Applicants also argue that the MPEP states that experimentation may be complex but does not necessarily make it undue, and that that is the test for enablement, as to whether the experimentation required is undue. The examiner does not argue this fact, it is not whether experimentation is required, but rather if it is undue experimentation. The examiner believes that the amount of experimentation required to determine which compounds are effective is indeed undue. One of skill in the art would be confronted with the undue burden of guessing which of the various immunomodulatory moieties they should use, and also guessing at what location to included the same in. Due to the enormous size of the genus claimed, one would be required to test millions of compounds to determine their efficacy, which the examiner believes is indeed considered undue experimentation. The breadth of the independent claim is such that the compound is of any size, from 3 to millions of nucleotides in length, and the immunomodulatory moiety can be included at any location in either the 3' or 5' direction. As such, the examiner believes that due to the size of the genus, one of skill in the art would indeed be required to

Art Unit: 1623

practice undue experimentation to determine which compounds indeed had efficacy. Especially in light of the fact that Yu et al. teaches that the location of the immunomodulatory agent is critical for immunostimulatory activity and that applicants own declarations show that even minor modifications, such as moving the immunomodulatory moiety one nucleotide in either direction, can produce completely opposite effects. Due to the fact that there is no known correlation between the location of the immunomodulatory moiety and the identity of the immunomodulatory moiety and thus one could not predict the results which might be obtained, and the fact that the breadth of the claim reads on millions of different possible combinations, the examiner believes that the skilled artisan would be confronted with an undue burden in determining which compounds would have efficacy as asserted.

Applicants also argue that claims in a related case were found to be enabled. This is not found to be convincing. It is well established that each application is treated on it's own merits. See *In re Giolito*, 530 F.2d 397, 188 USPQ 645 (CCPA 1976).

### ***Conclusion***

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

Art Unit: 1623

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Traviss C. McIntosh whose telephone number is 571-272-0657. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Traviss C. McIntosh III  
December 7, 2005

Shaojia A. Jiang  
Supervisory Patent Examiner  
Art Unit 1623

 12/9/05